New pacemaker technique aims to boost heart failure treatment

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. The patient is willing and able to comply with the protocol and has provided written informed consent; 2. Male or female patients aged 18 to 80 years; 3. Patients with ischemic or non-ischemic cardiomyopathy; 4. Symptomatic HF for at least 3 months prior to enrollment in the study; 5. New York Heart Association (NYHA) functional class HF ≥ II; 6. Patients with HF in sinus rhythm (SR) with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with LBBB morphology; 7. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration 130-149 ms with LBBB morphology; 8. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with non-LBBB morphology; 9. Patients with symptomatic persistent or permanent atrial fibrillation, HF with LVEF \< 40% (measured in the last 6 weeks prior to enrollment) and an uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration); 10. Patients with HF, LVEF \< 40% (measured in the last 6 weeks prior to enrollment) and indications for continuous ventricular pacing due to bradycardia; 11. Patients who have received a conventional pacemaker or an implanted cardioverter-defibrillator and who subsequently develop symptomatic HF with LVEF \< 40% (measured in the last 6 weeks prior to enrollment) despite optimal medical therapy, and who have a significant proportion of right ventricle pacing; 12. Optimal HF medical therapy. Exclusion criteria: 1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment; 2. Acute myocardial infarction within 3 months prior to enrollment; 3. Acute coronary syndrome; 4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting); 5. Patients listed for heart transplant; 6. Patients with implanted cardiac assist device; 7. Acute myocarditis; 8. Infiltrative myocardial disease; 9. Hypertrophic cardiomyopathy; 10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves; 11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age; 12. Mental or physical inability to participate in the study; 13. Patients unable or unwilling to cooperate within the study protocol; 14. Patients with rheumatic heart disease; 15. Mechanic tricuspid valve patients; 16. Patients with any serious medical condition that could interfere with this study; 17. Enrollment in another investigational drug or device study; 18. Patients not available for follow-up; 19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml/min/1.73 m2); 20. Life expectancy ≤ 12 months; 21. Participation in another telemonitoring concept.